<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Local contact(s)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Gregory</forename><surname>Effantin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ada</forename><surname>Yonath</surname></persName>
						</author>
						<title level="a" type="main">Local contact(s)</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">BC74694B4B0C044A98AB11C70C4D5222</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-05-23T14:56+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">unknown</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=1, consolidateHeader=1, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=true, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[], flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>mx-2183</keywords>
			</textClass>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Report:</head><p>The rapid emergence and spread of multi-drug resistant bacteria, alongside the negligible activity of the major pharma companies, cause a world crisis. Hence, the current situation is frequently described as a "catastrophe". Consequently, in 2014 the World Health Organization (WHO) warned that the antibiotic resistance is leading to "post-antibiotic era", and declared it a substantial threat to human health. Even the World Bank estimated that up to 3.8% of the global economy will be lost by 2050 because of resistance to antibiotics. The ribosomes, the multi-components (rRNA and rProteins) universal cellular particles that translate the genetic code into proteins are the target for ~40% of antibiotics in clinical use. During the last three decades the structure and function of the ribosomes have been the main objects of our scientific activities. Within this framework, we determined the structures of several bacterial ribosomes, and decifered how the currently used antibiotics paralyze them, as well as the molecular bases of the various resistance mecanisms. Among those we focused on the ribosome inhibition by Linezolid (Fig. <ref type="figure" target="#fig_0">1</ref>), which is a synthetic antibiotic drug that belongs to the class of oxazolidinones. It was approved by the Food and Drug Administration (FDA) in April 2000 to treat Grampositive pathogen infections. Being a synthetic drug, no preexisting resistance mechanisms were known, hence resistance to it was expected to emerge rather slowly. Despite these expectations, linezolid resistance was acquired by a specific 23S rRNA point mutation (G2576U) (E. coli rRNA numbering is used throughout) was aquiered by Staphylococcus aureus (SA) <ref type="bibr" target="#b1">(Tsiodras, Gold et al. 2001)</ref> approximately a year after it was approved for treatment. Together with resistance mechanisms identified later, linezolid resistance reached the level of &lt;1% of SA clinical isolates within 10 years <ref type="bibr" target="#b0">(Endimiani, Blackford et al. 2011</ref>). Recently, it was shown that new derivatives of linezolid (Fig. <ref type="figure" target="#fig_0">1</ref>) that were synthesized by our collaborators <ref type="bibr" target="#b2">(Yang, Chen et al. 2015)</ref> are useful inhibitors against SA strains. Moreover, superior in vitro inhibition of LYP-2 and YB-6 over LYP-1 and 1622 by 1-2 orders of magnitude was deteced. Consequently, we are studying the structures of the complexes of these compounds with the SA ribosome, aiming at the definition of the determinants for inhibition by these compounds as well as suggesting possible mechanisms for resistance and selectivity. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results:</head><p>Cryo-EM grids (Quantifoil 2/2) of the SA 70S ribosome (SA70S) complex samples were prepared from solutions of concentration of 1mg/ml. Data were collected on the Titan Krios FEI operating at 300 kV acceleration voltage at CM01 beamline, Grenoble, France and at a nominal underfocus of Δz = (-0.5)-(-1.5) μm using K2 GATAN camera and automated data collection with EPU software. The camera was calibrated at nominal magnification of 130K× resulting in 1.052 Å pixel size at the specimen level. The camera was set up to collect 40 frames, total exposure time was was 4 sec/movie with a dose of 20.3 e -Å 2 collecting 5 movie/hole.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fig. 2: cryo-EM micrograph of the 70S complex with compound YB-6, was collected at CM01 beamline, Grenoble, France with K2 camera onTitan Krios FEI.</head><p>All data processed using Relion 3 <ref type="bibr">(Scheres, 2018)</ref>. 6480 movies (Fig. <ref type="figure">2</ref>) were aligned by the whole image motion correction method. The contrast transfer function of every image was determined using CTFFIND4.1 of the RELION 3 workflow. Particle auto picking was done with a template (from auto particle picking). About 1,230,958 particles were picked. Due to relion's limitations we had to reduce the number of particles before 2D clasification, therfore we selected 575,600 particles with estimated resolution higher than 2.78 Å . 2D classification and selection of 45 (out of 380) classes yielded 510,675 particles (Fig. <ref type="figure" target="#fig_1">3</ref>). Performing 3D classification resulted in 10 classes. Among them, 6 classes were selected for 3D image reconstruction (Fig. <ref type="figure" target="#fig_3">5</ref>). 300,518 particles were used for 3D auto-refinement and the reconstructed map reached 3.00Å. After postprocessing the final resolution was 2.69Å. A CTF refinment, followed by Bayesian polishing was preformed, and the second 3D reconstruction reached 2.82Å. After post-processing the final resolution is 2.51Å. The high resolution of the resulting map enabled unambiguouse modeling of the nucleotides in the core of the ribosome. In addition, we could identify unmodeled electron density in the core of the ribosome, in close proximity to linezolid known binding site. that could fit our compaund (Fig. <ref type="figure" target="#fig_3">5</ref>).   </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 :</head><label>1</label><figDesc>Fig. 1: Chemical structure of linezolid derivatives that we plan to study in complex with SA ribosome. Linezolid structure is also shown for comparison purposes</figDesc><graphic coords="3,33.95,50.45,245.65,266.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 :</head><label>3</label><figDesc>Figure 3: 380 classes of the 1 st 2D classification of 510,675 particles (in red square are the 45 selected classes that were used for further analysis)</figDesc><graphic coords="4,33.95,193.55,452.15,148.35" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 4 :</head><label>4</label><figDesc>Figure 4: A. 10 classes of the 3D classification of 510,675 particles. 3 classes were selected (squared in red) for further analysis. B-C. two views (180 deg apart) of the 10 3D classes, (Figure 4B-C were created using Chimera).</figDesc><graphic coords="5,33.95,51.00,382.95,180.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 5 :</head><label>5</label><figDesc>Figure 5: The electron density map (blue) and a model of the nucleotides (gold) in the ribosome core, surrounding the expected binding site. The SA ribosome model was docked into the electron density and an extra electron density can be observed (pointed with black arrows). The extra density results from YB-6 that was bound to the ribosome. The two unmodeled electron densities blobs that were detacted, led to a speculatation that 2 molecules of YB-6 are bound (Figure 5 was created using Coot).</figDesc><graphic coords="5,33.95,287.90,477.15,296.40" type="bitmap" /></figure>
		</body>
		<back>

			<div type="funding">
<div><p>The department of structural Biology, The Weizmann institute of science, <rs type="person">Israel *Anat Bashan</rs>, The department of structural Biology, The Weizmann institute of science, <rs type="person">Israel Yehuda Halfon</rs> , The department of structural Biology, The Weizmann institute of science, <rs type="person">Israel Zohar Eyal</rs>, The department of structural Biology, The Weizmann institute of science, <rs type="person">Israel Ella Zimmerman</rs>, The department of structural Biology, The Weizmann institute of science, <rs type="person">Israel Giuseppe Cimicata</rs>, The department of structural Biology, The Weizmann institute of science, <rs type="person">Israel Donna Matzov</rs>, The department of structural Biology, The Weizmann institute of science, <rs type="person">Israel *Elinor Breiner Goldstein</rs> , The department of structural Biology, The Weizmann institute of science, Israel</p></div>
			</div>			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Emergence of Linezolid-Resistant &lt;i&gt;Staphylococcus aureus&lt;/i&gt; after Prolonged Treatment of Cystic Fibrosis Patients in Cleveland, Ohio</title>
		<author>
			<persName><forename type="first">Andrea</forename><surname>Endimiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Martha</forename><surname>Blackford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Elliot</forename><forename type="middle">C</forename><surname>Dasenbrook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michael</forename><forename type="middle">D</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Saralee</forename><surname>Bajaksouszian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Andrea</forename><forename type="middle">M</forename><surname>Hujer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Susan</forename><forename type="middle">D</forename><surname>Rudin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kristine</forename><forename type="middle">M</forename><surname>Hujer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vincent</forename><surname>Perreten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Louis</forename><forename type="middle">B</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michael</forename><forename type="middle">R</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michael</forename><forename type="middle">W</forename><surname>Konstan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Robert</forename><forename type="middle">A</forename><surname>Bonomo</surname></persName>
		</author>
		<idno type="DOI">10.1128/aac.01308-10</idno>
		<ptr target="http://www.weizmann.ac.il/sb/faculty_pages/Yonath/00Publications.html" />
	</analytic>
	<monogr>
		<title level="j">Antimicrobial Agents and Chemotherapy</title>
		<title level="j" type="abbrev">Antimicrob Agents Chemother</title>
		<idno type="ISSN">0066-4804</idno>
		<idno type="ISSNe">1098-6596</idno>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1684" to="1692" />
			<date type="published" when="2011-04">2011</date>
			<publisher>American Society for Microbiology</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">References: all in : http://www.weizmann.ac.il/sb/faculty_pages/Yonath/00Publications.html and Endimiani, A., M. Blackford, et al. (2011). &quot;Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.&quot; Antimicrobial agents and chemotherapy 55(4): 1684-1692.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Linezolid resistance in a clinical isolate of Staphylococcus aureus</title>
		<author>
			<persName><forename type="first">Sotirios</forename><surname>Tsiodras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Howard</forename><forename type="middle">S</forename><surname>Gold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">George</forename><surname>Sakoulas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">George</forename><forename type="middle">M</forename><surname>Eliopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christine</forename><surname>Wennersten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lata</forename><surname>Venkataraman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Robert</forename><forename type="middle">C</forename><surname>Moellering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mary</forename><forename type="middle">Jane</forename><surname>Ferraro</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(01)05410-1</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<title level="j" type="abbrev">The Lancet</title>
		<idno type="ISSN">0140-6736</idno>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="issue">9277</biblScope>
			<biblScope unit="page" from="207" to="208" />
			<date type="published" when="2001-07">2001</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Tsiodras, S., H. S. Gold, et al. (2001). &quot;Linezolid resistance in a clinical isolate of Staphylococcus aureus.&quot; The Lancet 358(9277): 207-208.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Discovery of a Teraryl Oxazolidinone Compound (&lt;i&gt;S&lt;/i&gt;)-&lt;i&gt;N&lt;/i&gt;-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1&lt;i&gt;H&lt;/i&gt;-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</title>
		<author>
			<persName><forename type="first">Tao</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gong</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zitai</forename><surname>Sang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuanyuan</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiaoyan</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ying</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Haiyue</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wei</forename><surname>Ang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jianying</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zhenling</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Guobo</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shengyong</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jingren</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuquan</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Youfu</forename><surname>Luo</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.5b00152</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Medicinal Chemistry</title>
		<title level="j" type="abbrev">J. Med. Chem.</title>
		<idno type="ISSN">0022-2623</idno>
		<idno type="ISSNe">1520-4804</idno>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="6389" to="6409" />
			<date type="published" when="2015-08-17">2015</date>
			<publisher>American Chemical Society (ACS)</publisher>
		</imprint>
	</monogr>
	<note>3-(3-Fluoro-4-(4-(pyridin-2-yl</note>
	<note type="raw_reference">Yang, T., G. Chen, et al. (2015). &quot;Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin- 2-yl)-</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Discovery of a Teraryl Oxazolidinone Compound (&lt;i&gt;S&lt;/i&gt;)-&lt;i&gt;N&lt;/i&gt;-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1&lt;i&gt;H&lt;/i&gt;-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</title>
		<author>
			<persName><forename type="first">Tao</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gong</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zitai</forename><surname>Sang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuanyuan</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiaoyan</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ying</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Haiyue</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wei</forename><surname>Ang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jianying</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zhenling</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Guobo</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shengyong</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jingren</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuquan</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Youfu</forename><surname>Luo</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.5b00152</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Medicinal Chemistry</title>
		<title level="j" type="abbrev">J. Med. Chem.</title>
		<idno type="ISSN">0022-2623</idno>
		<idno type="ISSNe">1520-4804</idno>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="6389" to="6409" />
			<date type="published" when="2015-08-17" />
			<publisher>American Chemical Society (ACS)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">H-pyrazol-1-yl) phenyl)-2-oxooxazolidin-5-yl) methyl) acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies.&quot; Journal of medicinal chemistry 58(16): 6389-6409.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">A Bayesian View on Cryo-EM Structure Determination</title>
		<author>
			<persName><forename type="first">Sjors</forename><forename type="middle">H W</forename><surname>Scheres</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jmb.2011.11.010</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Molecular Biology</title>
		<title level="j" type="abbrev">Journal of Molecular Biology</title>
		<idno type="ISSN">0022-2836</idno>
		<imprint>
			<biblScope unit="volume">415</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="406" to="418" />
			<date type="published" when="2012-01">2012</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">S. H. W. Scheres. 2012. A Bayesian View on Cryo-EM Structure Determination. J Mol Biol. 415(2): 406-418.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Features and development of &lt;i&gt;Coot&lt;/i&gt;</title>
		<author>
			<persName><forename type="first">Paul</forename><surname>Emsley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lohkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cowtan</surname></persName>
		</author>
		<idno type="DOI">10.1107/s0907444910007493</idno>
	</analytic>
	<monogr>
		<title level="j">Acta Crystallographica Section D Biological Crystallography</title>
		<title level="j" type="abbrev">Acta Crystallogr D Biol Crystallogr</title>
		<idno type="ISSN">0907-4449</idno>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="486" to="501" />
			<date type="published" when="2010-03-24">2010</date>
			<publisher>International Union of Crystallography (IUCr)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Emsley, Paul, et al. &quot;Features and development of Coot.&quot; Acta Crystallographica Section D: Biological Crystallography 66.4 (2010): 486-501.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
